SPAGO Stock Overview
A clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Spago Nanomedical AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.22 |
| 52 Week High | SEK 0.43 |
| 52 Week Low | SEK 0.15 |
| Beta | 2.02 |
| 1 Month Change | 2.80% |
| 3 Month Change | 11.68% |
| 1 Year Change | -29.26% |
| 3 Year Change | -94.39% |
| 5 Year Change | -97.84% |
| Change since IPO | -98.43% |
Recent News & Updates
Recent updates
Most Shareholders Will Probably Agree With Spago Nanomedical AB (publ)'s (STO:SPAGO) CEO Compensation
Jun 04
We're Not Worried About Spago Nanomedical's (STO:SPAGO) Cash Burn
Sep 21We're Interested To See How Spago Nanomedical (STO:SPAGO) Uses Its Cash Hoard To Grow
May 26Loss-Making Spago Nanomedical AB (publ) (STO:SPAG) Set To Breakeven
Mar 30We're Hopeful That Spago Nanomedical (NGM:SPAG) Will Use Its Cash Wisely
Feb 03
Loss-Making Spago Nanomedical AB (publ) (NGM:SPAG) Expected To Breakeven In The Medium-Term
Dec 11Shareholder Returns
| SPAGO | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 6.8% | 1.8% | -0.7% |
| 1Y | -29.3% | 14.2% | 12.1% |
Return vs Industry: SPAGO underperformed the Swedish Biotechs industry which returned 12.9% over the past year.
Return vs Market: SPAGO underperformed the Swedish Market which returned 12.8% over the past year.
Price Volatility
| SPAGO volatility | |
|---|---|
| SPAGO Average Weekly Movement | 9.2% |
| Biotechs Industry Average Movement | 8.3% |
| Market Average Movement | 5.8% |
| 10% most volatile stocks in SE Market | 12.1% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: SPAGO's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: SPAGO's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 12 | Mats Hansen | spagonanomedical.se |
Spago Nanomedical AB (publ), a clinical phase nanomedicine company, engages in the development of nanomedicines for cancer diagnostics and treatment primarily in Sweden. Its products include SpagoPix (SN132D), an MRI contrast agent, which is under Phase I development stage for the treatment of breast cancer, and under Phase II development stage for the treatment liver and pancreas cancer, as well as offers Tumorad (SN201), a radionuclide therapy for treatment of advanced and metastatic cancer, under Preclinical development stage. The company was formerly known as Spago Imaging AB (publ) and changed its name to Spago Nanomedical AB (publ) in May 2014.
Spago Nanomedical AB (publ) Fundamentals Summary
| SPAGO fundamental statistics | |
|---|---|
| Market cap | SEK 76.60m |
| Earnings (TTM) | -SEK 32.51m |
| Revenue (TTM) | SEK 6.91m |
11.1x
P/S Ratio-2.4x
P/E RatioIs SPAGO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPAGO income statement (TTM) | |
|---|---|
| Revenue | SEK 6.91m |
| Cost of Revenue | SEK 14.27m |
| Gross Profit | -SEK 7.36m |
| Other Expenses | SEK 25.15m |
| Earnings | -SEK 32.51m |
Last Reported Earnings
Dec 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.093 |
| Gross Margin | -106.41% |
| Net Profit Margin | -470.26% |
| Debt/Equity Ratio | 0% |
How did SPAGO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/21 14:37 |
| End of Day Share Price | 2025/02/21 00:00 |
| Earnings | 2024/12/30 |
| Annual Earnings | 2024/12/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Spago Nanomedical AB (publ) is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Klas Palin | Carnegie Commissioned Research |
| Klas Palin | Penser Access |
| Johan Unnerus | Redeye |